Enterprise Value

146.9M

Cash

106.2M

Avg Qtr Burn

-21.4M

Short % of Float

4.76%

Insider Ownership

10.01%

Institutional Own.

27.66%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
COMP360 Details
Treatment Resistant Depression

Phase 3

Data readout

RL-007 Details
Cognitive Dysfunction, Schizophrenia

Phase 2b

Data readout

BPL-003 (Intranasal 5-MeO-DMT) Details
Treatment Resistant Depression

Phase 2b

Data readout

COMP360 Details
Post-traumatic stress disorder

Phase 2

Update

GRX-917 Details
Anxiety Disorders

Phase 2

Update

Phase 2a

Data readout

ELE-101 Details
Major depressive disorder

Phase 1/2

Data readout

Ibogaine (DMX-1002) Details
Opioid use disorder

Phase 1/2

Update

VLS-01 Details
Treatment Resistant Depression

Phase 1b

Data readout

Phase 1

Update

PCN-101 (R-Ketamine) Details
Treatment Resistant Depression

Phase 1

Update

PCN-101 Details
Treatment Resistant Depression

Failed

Discontinued